Silk microspheres for encapsulation and controlled release
A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments.
1. A pharmaceutical formulation comprising silk fibroin microspheres, wherein the silk fibroin microspheres are produced by a method comprising:
a) mixing a silk fibroin solution with a lipid composition, wherein the silk fibroin solution contains at least one therapeutic agent;
b) lyophilizing the mixture;
c) combining the lyophilized material with a dehydration medium for a sufficient period of time to at least partially dehydrate the silk fibroin solution and induce β-sheet structures in the silk fibroin; and
d) removing at least a portion of the lipids to form silk fibroin microspheres, wherein the therapeutic agent is encapsulated in the silk fibroin microspheres, and wherein at least 75% of the microspheres are spherical or substantially spherical, and wherein the microspheres have a smooth surface morphology.
2. The formulation of claim 1 , wherein the average size of the microspheres is less than 2.0 μm.
3. The pharmaceutical formulation of claim 1 , wherein the microspheres contain about 1 to about 25% of lipid components by weight.
4. The pharmaceutical formulation of claim 1 , wherein the lipid components are selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC); and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC).
5. The pharmaceutical formulation of claim 1 , wherein the therapeutic agent is selected from the group consisting of proteins, peptides, nucleic acids, peptide nucleic acids, aptamers, antibodies, growth factors, cytokines, enzymes, small molecules, and combinations thereof.
6. The pharmaceutical formulation of claim 1 , wherein the therapeutic agent is selected from the group consisting of morphogenetic protein 2 (BMP-2), insulin-like growth factor I and II (IGF-I and II), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), transforming growth factors-β (TGFs-β), transforming growth factors-α, erythropoietin (EPO), interferon α and γ, interleukins, tumor necrosis factor α and β, insulin, antibiotics, adenosine, and combinations thereof.
7. The pharmaceutical formulation of claim 1 , wherein at least 75% of the microspheres have a diameter ranging from about 1 to about 3 microns.
8. The pharmaceutical formulation of claim 1 , wherein the silk fibroin and the therapeutic agent are located in separate layers or domains of the microspheres.
9. The pharmaceutical formulation of claim 1 , wherein the lipids in the silk fibroin microspheres forms unilamellar or multilamellar structures.
10. A drug delivery composition comprising a therapeutic agent encapsulated in crosslinked silk fibroin microspheres,
wherein the microspheres comprise:
lipid components in an amount no greater than 20% of the microspheres by weight; and
silk fibroin, 50% or more of which is in β-sheet form,
wherein the lipid components are integrated with the silk fibroin.
11. The composition of claim 10 , wherein the therapeutic agent is released in a controlled-release manner from the microspheres.
12. The composition of claim 10 , wherein the microspheres contain less than 5% lipid components by weight.
13. The composition of claim 10 , wherein the weight percentage of the microspheres that is silk fibroin is at least 50%.
14. The composition of claim 10 , wherein the average size of the microspheres is less than 2.0 μm.
15. The composition of claim 10 , wherein the crosslinking of the silk fibroin microspheres was induced by exposing the silk fibroin to methanol or sodium chloride.
16. The composition of claim 10 , wherein the lipid components are selected from the group consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC); 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE); 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC); 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC); and combinations thereof.
17. The composition of claim 10 , wherein the therapeutic agent is selected from the group consisting of proteins, peptides, nucleic acids, peptide nucleic acids, aptamers, antibodies, growth factors, cytokines, enzymes, small molecules, and combinations thereof.
18. The composition of claim 10 , wherein the therapeutic agent is selected from the group consisting of morphogenetic protein 2 (BMP-2), insulin-like growth factor I and II (IGF-I and II), epidermal growth factor (EGF), platelet-derived growth factor (PDGF), fibroblast growth factors (FGFs), transforming growth factors-β (TGFs-β), transforming growth factors-α, erythropoietin (EPO), interferon α and γ, interleukins, tumor necrosis factor α and β, insulin, antibiotics, adenosine, and combinations thereof.
19. The composition of claim 10 , wherein at least 75% of the microspheres have a diameter ranging from about 1 to about 3 microns.
20. The composition of claim 10 , wherein the silk fibroin and the therapeutic agent are located in separate layers or domains.
21. The composition of claim 10 , wherein the lipid components in the silk fibroin microspheres form unilamellar or multilamellar structures.
22. A method of preparing silk fibroin microspheres, the method comprising:
a) providing a silk fibroin-lipid mixture;
b) lyophilizing the silk fibroin-lipid mixture;
c) combining the lyophilized silk fibroin-lipid mixture with a dehydration medium for a sufficient period of time to at least partially induce β-sheet structures in the silk fibroin; and
d) removing at least a portion of the lipids to form silk fibroin microspheres.
23. The method of claim 22 , wherein the method further comprises freeze-thawing the silk fibroin-lipid mixture prior to lyophilizing.
24. The method of claim 22 , wherein the dehydration medium comprises methanol or NaCl.
25. The composition of claim 10 , wherein at least 75% of the microspheres are spherical or substantially spherical.
26. The composition of claim 10 , wherein the microspheres have a smooth surface morphology.